CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
As winter weather continues to move through parts of the US, we would like to remind you it may be n...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...